Roswell Working on a new brain cancer vaccine
Link below: Promising new cancer vaccine - channel 2 WGRZ
Phase 2 of the clinical trials will involve 50-patients. It will be evaluated in a larger trial to assess its effectiveness for patients with advanced brain tumors and a new Phase 1 clinical trial for multiple myeloma patients.
Those in the initial phase received a series of up to four injections of SurVaxM at two-week intervals. Most patients developed T cell and antibody responses to survivin, the vaccine target. The average expected survival time for recurrent glioblastoma patients is approximately only seven months when receiving standard therapy.
No comments:
Post a Comment